Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2012 February;56(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2012 February:56(1):4-16

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi

 

REVIEWS  THE IMPACT OF MOLECULAR IMAGING ON THE MANAGEMENT OF MOVEMENT DISORDERS 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2012 February:56(1):4-16

Copyright © 2012 EDIZIONI MINERVA MEDICA

lingua: Inglese

The molecular basis of dopaminergic brain imaging in Parkinson’s disease

Seibyl J. 1, 2, Russell D. 1, 2, Jennings D. 1, Marek K. 1, 2

1 Institute for Neurodegenerative Disorders, Molecular NeuroImaging, LLC, New Haven, Connecticut; 2 Yale University School of Medicine, New Haven, CT, USA


PDF


The central role of dopamine neuronal loss in Parkinson’s disease provides a clear pathologic framework and rationale for imaging the system both to interrogate dynamic pathophysiologic changes as well as to aid in diagnosis and clinical management. Recent post mortem studies of Parkinson’s brain provide a much fuller depiction of the inexorable and progressive topology of pathophysiologic changes, including brain alpha-synuclein deposition. This informs PET and SPECT evaluations for testing hypotheses regarding the course of degeneration in longitudinal studies of Parkinson’s disease patients. Recent work has underscored the subtlety of change in the dopaminergic neuronal system and its neural connections as a function of disease status and treatment. The interplay between other neurochemical brain systems and dopamine elucidates potential new targets for therapeutic intervention across the stages of the disease.

inizio pagina